Fludarabine, cytarabine, granulocyte colony-stimulating factor and idarubicin for relapsed childhood acute myeloid leukemia-Reference-Cited by-同舟云学术

Fludarabine, cytarabine, granulocyte colony-stimulating factor and idarubicin for relapsed childhood acute myeloid leukemia

Published:2017-10 Issue:10 Volume:59 Page:1046-1052
ISSN:1328-8067
Container-title:Pediatrics International
language:en
Short-container-title:Pediatrics International

Author:

Nakayama Hideki¹²³^ORCID,Tomizawa Daisuke⁴,Tanaka Shiro⁵,Iwamoto Shotaro⁶,Shimada Akira⁷^ORCID,Saito Akiko M³,Yamashita Yuka³,Moritake Hiroshi⁸,Terui Kiminori⁹,Taga Takashi¹⁰,Matsuo Hidemasa¹¹^ORCID,Kosaka Yoshiyuki¹²,Koh Katsuyoshi¹³,Hosoi Hajime¹⁴,Kurosawa Hidemitsu¹⁵,Isoyama Keiichi¹⁶,Horibe Keizo³,Mizutani Shuki¹⁷,Adachi Souichi¹¹

Affiliation:

1. Department of Pediatrics; National Hospital Organization Kyushu Cancer Center; Fukuoka Japan

2. Department of Pediatrics; National Hospital Organization Fukuoka-Higashi Medical Center; Fukuoka Japan

3. Clinical Research Center; National Hospital Organization Nagoya Medical Center; Nagoya Japan

4. Division of Leukemia and Lymphoma; Children's Cancer Center; National Center for Child Health and Development; Tokyo Japan

5. Department of Clinical Biostatistics; Graduate School of Medicine; Kyoto University; Kyoto Japan

6. Department of Pediatrics; Mie University Graduate School of Medicine; Tsu Mie Japan

7. Department of Pediatrics; Okayama University; Okayama Japan

8. Department of Pediatrics; Faculty of Medicine; University of Miyazaki; Miyazaki Japan

9. Department of Pediatrics; Hirosaki University Graduate School of Medicine; Hirosaki Japan

10. Department of Pediatrics; Shiga University of Medical Science; Ohtsu Japan

11. School of Human Health Science; Faculty of Medicine; Kyoto University; Kyoto Japan

12. Department of Pediatric Hematology/Oncology; Hyougo Prefectural Kobe Children's Hospital; Kobe Japan

13. Department of Hematology/Oncology; Saitama Children's Medical Center; Saitama Japan

14. Department of Pediatrics; Kyoto Prefectural University of Medicine; Kyoto Japan

15. Department of Pediatrics; Dokkyo Medical University; Tochigi Japan

16. Department of Pediatrics; Showa University Fujigaoka Hospital; Yokohama Japan

17. Department of Pediatrics and Developmental Biology; Tokyo Medical and Dental University; Tokyo Japan

Funder

Japan Agency for Medical Research and Development

Publisher

Wiley

Subject

Pediatrics, Perinatology and Child Health

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/ped.13378/fullpdf

Reference38 articles.

1. Risk-stratified therapy and the intensive use of cytarabine improves the outcome in childhood acute myeloid leukemia: The AML99 trial from the Japanese Childhood AML Cooperative Study Group;Tsukimoto;J. Clin. Oncol.,2009

2. Minimal residual disease-directed therapy for childhood acute myeloid leukaemia; result of the AML02 multicentre trial;Rubnitz;Lancet Oncol.,2010

3. Results of a randomized trial in children with acute myeloid leukemia: Medical Research Council AML12 trial;Gibson;Br. J. Haematol.,2011

4. Randomized trial comparing liposomal daunorubicin with idarubicin as induction for pediatric acute myeloid leukemia: Results from Study AML-BFM 2004;Creutzig;Blood,2013

5. Results of the AIEOP AML 2002/01 multicenter prospective trial for the treatment of children with acute myeloid leukemia;Pession;Blood,2013

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Treatment results of children and adolescents with relapsed AML who were initially treated according to the AML-MM-2006 protocol;Russian journal of hematology and transfusiology;2023-07-17

2. NK cell defects: implication in acute myeloid leukemia;Frontiers in Immunology;2023-05-09

3. TREATMENT RESULTS OF CHILDREN AND ADOLESCENTS WITH RELAPSED AML WHO WERE INITIALLY TREATED ACCORDING TO THE AML-MM-2006 PROTOCOL;GEMATOL TRANSFUZIOL;2023

4. Homoharringtonine combined with cladribine and aclarubicin (HCA) in acute myeloid leukemia: A new regimen of conventional drugs and its mechanism;Oxidative Medicine and Cellular Longevity;2022-07-13

5. Immunotherapy in AML: a brief review on emerging strategies;Clinical and Translational Oncology;2021-06-23